It found trading -44.35% off 52-week high price. On the other end, the stock has actually been kept in mind 854.42% away from the low cost over the last 52-weeks.
” In parallel, pelareorep continues to get validation and recognition amongst the medical community,” mentioned Dr. Rita Laeufle, Chief Medical Officer at Oncolytics. This is a crucial differentiator for pelareorep and speaks to the breadth of commercial opportunities that may be available to Oncolytics beyond our lead indication of breast cancer. Other chances include extra synergies, such as the recent information from preclinical combinations with CDK 4/6 inhibitors that was presented at the International Oncolytics Virus Conference in October.
Oncolytics Biotech ® Inc. (ONCY) recently reported its financial results and functional highlights for the quarter ended September 30, 2019. All dollar quantities are expressed in Canadian currency unless otherwise kept in mind.
The company has 23.99 M of outstanding shares and 23.99 M shares were drifted in the market. According to the most current quarter its current ratio was 3.8 that represents businesss ability to meet its current monetary obligations. The price moved ahead of 0.86% from the mean of 20 days, 65.40% from mean of 50 days SMA and performed 130.07% from mean of 200 days price. Businesss efficiency for the week was 16.72%, 97.06% for month and YTD performance stayed -29.62%.
Operating cost for the third quarter of 2019 was $1.8 M contrast to $1.5 M in the third quarter 2018
As at November 8, 2019, the company had an unrestricted variety of licensed common show 26,357,724 normal shares issued and outstanding, 16,443,500 warrants exercisable into 1,730,894 ordinary shares with a $9.025 strike rate, 3,567,989 warrants with a US$ 0.90 strike rate, and 1,577,230 options and share systems.
At September 30, 2019, the company mentioned $12.3 M in money and money equivalents.
On 22 Jan 2020, Oncolytics Biotech Inc. (NASDAQ: ONCY) altered -5.63% to recent value of $3.35. It spotted trading -44.35% off 52-week high price. On the other end, the stock has actually been kept in mind 854.42% away from the low cost over the last 52-weeks.
The rate moved ahead of 0.86% from the mean of 20 days, 65.40% from mean of 50 days SMA and performed 130.07% from mean of 200 days cost.
Research and development cost for the 3rd quarter of 2019 was $1.6 M contrast to $1.9 M in the 3rd quarter 2018.
The net loss for the third quarter of 2019 was $3.5 M contrast to $3.3 M in the 3rd quarter 2018, which corresponds to a bottom line of $0.16 per share in 2019 contrast to a net loss of $0.20 per share in 2018.